蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响

张薇; 陈华剑

doi:10.16016/j.1000-5404.201812145

您当前的位置：

首页 >

文章列表页 >

蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响

基础医学 | 更新时间：2026-01-09

- 蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响
- Effect of protease activated receptor 2 on proliferation and apoptosis of hepatocellular carcinoma cells
- 第三军医大学学报 2019年41卷第13期页码：1232-1238
- 作者机构：
  
  400014 重庆，重庆市急救医疗中心检验科
- 作者简介：
  
  [陈华剑, E-mail: chenhuajian0201@163.com CHEN Huajian, E-mail: chenhuajian0201@163.com
- 基金信息：
- DOI：10.16016/j.1000-5404.201812145
  中图分类号： R394.3;R730.23;R735.7
- 收稿：2018-12-18，
  
  修回：2019-02-26，
  
  纸质出版：2019-07-15
- 稿件说明：
移动端阅览
张薇, 陈华剑. 蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响[J]. 第三军医大学学报, 2019,41(13):1232-1238.

Wei ZHANG, Huajian CHEN. Effect of protease activated receptor 2 on proliferation and apoptosis of hepatocellular carcinoma cells[J]. Journal of Third Military Medical University, 2019, 41(13): 1232-1238.
张薇, 陈华剑. 蛋白酶激活受体2对肝癌细胞增殖及凋亡的影响[J]. 第三军医大学学报, 2019,41(13):1232-1238. DOI： 10.16016/j.1000-5404.201812145.

Wei ZHANG, Huajian CHEN. Effect of protease activated receptor 2 on proliferation and apoptosis of hepatocellular carcinoma cells[J]. Journal of Third Military Medical University, 2019, 41(13): 1232-1238. DOI： 10.16016/j.1000-5404.201812145.

摘要

目的

探讨蛋白酶激活受体2(protease activated receptor 2，PAR2)对肝癌细胞增殖及凋亡的影响。

方法

RT-qPCR检测100例肝癌组织及相应的癌旁组织中PAR2 mRNA的表达，并分析肝癌患者临床病理参数与PAR2表达水平之间的相关性。RT-qPCR及Western blot检测原代肝细胞、永生化肝细胞及肝癌细胞中PAR2 mRNA及蛋白的表达。采用siRNA靶向沉默PAR2的表达，MTS法及软琼脂集落形成实验检测沉默PAR2对肝癌细胞增殖的影响，流式细胞术及PARP的剪切检测沉默PAR2对肝癌细胞凋亡的影响。RT-qPCR筛选PAR2调控的凋亡靶基因，并用Western blot进行验证。

结果

肝癌组织中PAR2 mRNA的相对表达量为(1.86±1.26)，明显高于癌旁组织(0.96±0.66，

0.001)，且PAR2在肝癌组织中表达上调与肿瘤的长径以及分期均相关(

=0.002)。PAR2在肝癌细胞中的表达高于永生化肝细胞和原代肝细胞(

0.05)。沉默PAR2抑制肝癌细胞SK-Hep-1和PLC/PRF/5的活性(

0.01)及集落形成能力(

0.01)，沉默PAR2导致SK-Hep-1和PLC/PRF/5细胞凋亡比例分别增加109%(

0.01)和112%(

0.01)；且沉默PAR2增加了Bax mRNA和蛋白表达水平。

结论

PAR2可通过影响Bax的表达而影响肝癌细胞的增殖与凋亡。

Abstract

Objective

To demonstrate the role of protease activated receptor 2 (PAR2) in the proliferation and apoptosis of hepatocellular carcinoma (HCC) cells.

Methods

Firstly

the mRNA expression level of PAR2 in the cancer and para-cancerous tissues of 100 HCC patients were detected by RT-qPCR. Then the association between multiple clinicopathologic parameters and PAR2 mRNA level in HCC tissues were illustrated by statistical analysis. Secondly

the mRNA and protein levels of PAR2 in primary hepatocyte (PHH cells)

immortalized hepatocyte (MIHA cells) and hepatoma cell lines (PLC/PRF/5

SK-Hep-1

HepG2 and Hep3B) were determined by RT-qPCR and Western blotting. Thirdly

the proliferation of HCC cells was analyzed by MTS and soft agar assay after the silence of PAR2. Moreover

the apoptosis of HCC cells was analyzed by flow cytometry and the cleavage of PARP after the silence of PAR2. Finally

the apoptosis target genes were screened by RT-qPCR

and then validated by Western blotting.

Results

The relative mRNA level of PAR2 was 1.86±1.26 in HCC tissues

which was significantly higher than that in the adjacent tissues (0.96±0.66

0.001)

and the up-regulation of PAR2 in HCC tissues was positively correlated with tumor

size and tumor stage (

=0.002). Also

the expression level of PAR2 in hepatoma cell lines was significantly higher than those in immortalized hepatocytes and primary hepatocytes (

0.05). Importantly

silence of PAR2 inhibited the cell viability and colony forming ability in SK-Hep-1 and PLC/PRF/5 cells (both

0.01)

and also induced the apoptotic rate increased to 109% and 112% in SK-Hep-1 and PLC/PRF/5 cells (

0.01)

separately. What's more

the silence of PAR2 up-regulate the expression of Bax at mRNA and protein levels.

Conclusion

PAR2 affects the proliferation and apoptosis of HCC cells through regulating the expression of Bax.

关键词

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.

HASSAN M, WATARI H, ABUALMAATY A, et al . Apoptosis and molecular targeting therapy in cancer[J ] . Biomed Res Int, 2014, 2014: 150845. DOI:10.1155/2014/150845.

MCCULLOCH K, MCGRATH S, HUESA C, et al . Rheumatic disease: protease-activated receptor-2 in synovial joint pathobiology[J ] . Front Endocrinol (Lausanne), 2018, 9: 257. DOI:10.3389/fendo.2018.00257.

UNGEFROREN H, GIESELER F, KAUFMANN R, et al . Signaling crosstalk of TGF-β/ALK5 and PAR2/PAR1: A complex regulatory network controlling fibrosis and cancer[J ] . Int J Mol Sci, 2018, 19(6): E1568. DOI:10.3390/ijms19061568.

POSMA J J, GROVER S P, HISADA Y, et al . Roles of coagulation proteases and PARs (protease-activated receptors) in mouse mo dels of inflammatory diseases[J ] . Arterioscler Thromb Vasc Biol, 2019, 39(1): 13-24. DOI:10.1161/ATVBAHA.118.311655.

DAS K, PRASAD R, ROY S, et al . The protease activated receptor 2 promotes rab5a mediated generation of pro-metastatic microvesicles[J ] . Sci Rep, 2018, 8(1): 7357. DOI:10.1038/s41598-018-25725-w.

CARVALHO É, HUGO DE ALMEIDA V, RONDON A M R, et al . Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells[J ] . Biochem Biophys Res Commun, 2018, 504(1): 270-276. DOI:10.1016/j.bbrc.2018.08.169.

DAS K, PRASAD R, ANSARI S A, et al . Matrix metalloproteinase-2: A key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling[J ] . Biomed Pharmacother, 2018, 105:395-406. DOI:10.1016/j.biopha.2018.05.155.

ZHOU B, ZHOU H, LING S, et al . Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2[J ] . Oncol Rep, 2011, 25(2): 503-511. DOI:10.3892/or.2010.1077..

GUO D, ZHOU H, WU Y, et al . Involvement of ERK1/2/NF-kappaB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620[J ] . Tumor Biol, 2011, 32(5): 921-930. DOI:10.1007/s13277-011-0194-1.

HUANG S H, LI Y, CHEN H G, et al . Activation of proteinase-activated receptor 2 prevents apoptosis of lung cancer cells[J ] . Cancer Invest, 2013, 31(9): 578-581. DOI: 10.3109/07357907.2013.845674.

HAN S, LEE C W, TREVINO J G, et al . Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma[J ] . PLoS ONE, 2013, 8(10): e76667. DOI:10.1371/journal.pone.0076667.

PENG W T, SUN W Y, LI X R, et al . Emerging roles of G protein-coupled receptors in hepatocellular carcinoma[J ] . Int J Mol Sci, 2018, 19(5): E1366. DOI:10.3390/ijms19051366.

FEIGIN M E, XUE B, HAMMELL M C, et al . G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion[J ] . Proc Natl Acad Sci U S A, 2014, 111(11): 4191-4196. DOI:10.1073/pnas.1320239111.

张晓飞, 董琼珠, 薛裕华, 等.蛋白酶激活受体1在癌旁组织中的高表达与肝癌早期患者术后预后不良相关[J].中华肝脏病杂志, 2011, 19(4): 266-270. DOI: 10.3760/cma.j.issn.1007-3418.2011.04.009.

ZHANG X F, DONG Q Z, XUE Y H, et al . High expression of thrombin receptor PAR1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma in early stage[J ] . Chin J Hepatol, 2011, 19(4): 266-270. DOI: 10.3760/cma.j.issn.1007-3418.2011.04.009.

MUSSBACH F, HENKLEIN P, WESTERMANN M, et al . Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation[J ] . J Cancer Res Clin Oncol, 2015, 141(5): 813-825. DOI: 10.1007/s00432-014-1863-4.

CARNEIRO-LOBO T C, LIMA M T, MARIANO-OLIVEIRA A, et al . Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients[J ] . Oncol Rep, 2014, 31(2): 679-686. DOI:10.3892/or.2013.2880.

JIANG Y H, YAU M K, LIM J, et al . A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells[J ] . J Pharmacol Exp Ther, 2018, 364(2): 246-257. DOI:10.1124/jpet.117.245027.

HUGO DE ALMEIDA V, GUIMARÃES I D S, ALMENDRA L R, et al . Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer[J ] . Oncotarget, 2018, 9(55): 30594-30609. DOI:10.18632/oncotarget.25748.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

静息期精原前体细胞Rb1基因敲除致精原干细胞特化异常机制初探

Hsa_circ_0000711在人肝癌细胞系中的功能研究

生物钟基因PER1调控口腔鳞癌细胞中BAX、BCL2和PCNA表达的昼夜节律

靶向抑制DNAJC1基因对多发性骨髓瘤细胞凋亡和增殖的影响